ArticleSkin health and disease2022
Development of a topical bacteriophage gel targeting
Article in Skin health and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- The human skin virome: Ecological dynamics, aberrant profiles, and therapeutic opportunities.Cell host & microbe · 2026Review
- A Global Delphi Consensus on Acne and the Microbiome: Integrating International Expertise for Innovative Prevention and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Evolving Microbial Paradigm in Acne.Biomolecules · 2026Review
- Pseudolysogeny-mediated evolutionary trade-offs favor phage therapy by limiting antibiotic resistance and virulence in Cutibacterium acnes.Scientific reports · 2026Article
- Skin microbiome and cutaneous aging mechanisms and clinical implications.Frontiers in microbiology · 2026Review
- Review
- The human skin microbiome: from metagenomes to therapeutics.Nature reviews. Microbiology · 2025Review
- Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications.Pharmaceutics · 2025Review
- The future of phage therapy in the USA.Trends in molecular medicine · 2025Review
- Microbiome-Based Products: Therapeutic Potential for Inflammatory Skin Diseases.International journal of molecular sciences · 2025Review
- Safety Evaluation of Topical Products Containing Live Cultures and Ferment of Cutibacterium Acnes Subspecies Defendens Strain XYCM42 in Individuals Predisposed to Acne Vulgaris.The Journal of clinical and aesthetic dermatology · 2025Article
- Antibacterial activity and impact on keratinocyte cell growth ofCurrent research in microbial sciences · 2025Article
- The Role of the Skin Microbiome in Acne: Challenges and Future Therapeutic Opportunities.International journal of molecular sciences · 2024Review
- Characterization and genomic analysis of PA-56Heliyon · 2024Article
- Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections.Heliyon · 2024Review
- Bacteriophages from human skin infecting coagulase-negative Staphylococcus: diversity, novelty and host resistance.Scientific reports · 2024Article
- Phage Delivery Strategies for Biocontrolling Human, Animal, and Plant Bacterial Infections: State of the Art.Pharmaceutics · 2024Review
- Application of bacteriophage φPaP11-13 attenuates ratMicrobiology spectrum · 2024Article
- Review
- Bioprospecting the Skin Microbiome: Advances in Therapeutics and Personal Care Products.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Topical antibiotics are frequently used to treat acne vulgaris. Their prolonged use, often for longer durations than recommended, has led to antibiotic resistance in Objectives: To identify and characterize Methods: Phages were isolated by conventional microbiological methods also used to examine their breadth of host range on different Results: Wide host range phages that also target antibiotic resistant Conclusions: Combined in silico and ex vivo approaches successfully predicted the observed safety and efficacy of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.